FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper-Reference-Cited by-同舟云学术

FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper

Published:2017-10 Issue:1 Volume:147 Page:3-10
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Herzog Thomas J.,Ison Gwynn,Alvarez Ronald D.,Balasubramaniam Sanjeeve,Armstrong Deborah K.,Beaver Julia A.,Ellis Annie,Tang Shenghui,Ford Peg,McKee Amy,Gershenson David M.,Kim Geoffrey,Monk Bradley J.,Pazdur Richard,Coleman Robert L.^ORCID

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference47 articles.

1. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop;Bast;Gynecol. Oncol.,2007

2. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper;Herzog;Gynecol. Oncol.,2014

3. SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm;Herzog;Gynecol. Oncol.,2014

4. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer;Vergote;N. Engl. J. Med.,2010

5. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial;Kehoe;Lancet,2015

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients—A Systematic Review and Meta-Analysis;Pharmaceuticals;2024-08-21

2. Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment;Frontiers in Drug Delivery;2024-02-01

3. Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions;International Journal of Gynecologic Cancer;2023-11

4. Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival;Gynecologic Oncology;2023-10

5. Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review;International Journal of Gynecologic Cancer;2023-08-29